[Sirnaomics: Because the company was included in the import ban list by the FDA, the signing of a return and refund agreement is expected to reduce net profit by 84.2466 million yuan] On November 9th, Sirnaomics (688117.SH) announced that the company and its wholly-owned subsidiary Sirnaomics signed a "Return and Refund Agreement" with US customer A. Because Sirnaomics was included in the import ban list by the FDA, the two parties negotiated to return some peptide APIs, and the company needs to refund US$24.9596 million in installments. The company achieved revenue of 741 million yuan and net profit of 171 million yuan in the first three quarters of 2026. The refund is expected to reduce this year's main business income by 163 million yuan, total profit by 99.1137 million yuan, and net profit is expected to decrease by 84.2466 million yuan, and does not involve adjustments to previous accounting data.